Glaxo Smithkline Result Review
Tuesday, April 22, 2008GlaxoSmithKline Pharma's (GSK Pharma) Q1CY08 results were broadly in line with our expectations. Net sales have decreased by 0.7% YoY to Rs 4.2bn. However, excluding the contribution of the fine chemicals business which was divested in September 2007, net sales have increased by 5.3%, in line with estimates. Priority products witnessed a healthy growth of 9% YoY, while the sales of price-controlled products were affected by pipeline inventory adjustments owing to excise-related price changes. The EBITDA margin has expanded marginally by 30bps YoY to 36.4% while higher non-operational income resulted in 8.9% growth in PAT to Rs 1.2bn
Recent Corporate Earnings / Breaking News
- Private Equity in Real Estate
- Fresenius Kabi acquires 100% stake in Dabur Pharma...
- Trident Homescapes opens in Chandigarh
- Satyam to acquire S&V Management Consultants
- Subex bags Verizon's excellence award
- Suzlon Energy secures orders
- Virat Crane to demerge its real estate business
- Wipro appoints joint CEOs for IT business
- Shoppers Stop wins emerging market retailer of the...
- KEC International wins Power Grid contract
